title: Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
abstract: Immunodominant epitopes are known to suppress a primary immune response to other antigenic determinants by a number of mechanisms. Many pathogens have used this strategy to subvert the immune response and may be a mechanism responsible for limited vaccine efficacies. HIV-1 vaccine efficacy appears to be complicated similarly by a limited, immunodominant, isolate-restricted immune response generally directed toward determinants in the third variable domain (V3) of the major envelope glycoprotein, gp120. To overcome this problem, we have investigated an approach based on masking the V3 domain through addition of N-linked carbohydrate and reduction in net positive charge. N-linked modified gp120s were expressed by recombinant vaccinia virus and used to immunize guinea pigs by infection and protein boosting. This modification resulted in variable site-specific glycosylation and antigenic dampening, without loss of gp120/CD4 binding or virus neutralization. Most importantly, V3 epitope dampening shifted the dominant type-specific neutralizing Ab response away from V3 to an epitope in the first variable domain (V1) of gp120. Interestingly, in the presence of V3 dampening V1 changes from an immunodominant non-neutralizing epitope to a primary neutralizing epitope with broader neutralizing properties. In addition, Ab responses were also observed to conserved domains in C1 and C5. These results suggest that selective epitope dampening can lead to qualitative shifts in the immune response resulting in second order neutralizing responses that may prove useful in the fine manipulation of the immune response and in the development of more broadly protective vaccines and therapeutic strategies.
authors.affiliation: Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center (NCI-FCRDC), MD 21702, USA. garrity@sri.org
authors.forename: R R
authors.initials: RR
authors.lastname: Garrity
authors.forename: G
authors.initials: G
authors.lastname: Rimmelzwaan
authors.forename: A
authors.initials: A
authors.lastname: Minassian
authors.forename: W P
authors.initials: WP
authors.lastname: Tsai
authors.forename: G
authors.initials: G
authors.lastname: Lin
authors.forename: J J
authors.initials: JJ
authors.lastname: de Jong
authors.forename: J
authors.initials: J
authors.lastname: Goudsmit
authors.forename: P L
authors.initials: PL
authors.lastname: Nara
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D000914:Antibodies, Viral / Q000276:immunology*; D002460:Cell Line; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016056:Immunodominant Epitopes / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D014162:Transfection
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015699:HIV Envelope Protein gp120; D016056:Immunodominant Epitopes